Product image of Immunate (Human Coagulation Factor Viii, Human Von Willebrand Factor) supplied by GNH India

Immunate

Active Ingredient:
Human Coagulation Factor Viii, Human Von Willebrand Factor
Origin:
EU

Immunate (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Human Coagulation Factor VIII and Human Von Willebrand Factor, the active ingredient in Immunate, is a hemostatic agent presented as a biologic for intravenous use. It replaces deficient clotting factors to treat hemophilia A and von Willebrand disease in patients requiring factor replacement therapy.

GNH India supplies Immunate as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Baxalta Innovations Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Immunate acts on the intrinsic coagulation pathway and platelet adhesion mechanisms to manage inherited bleeding disorders.
  • Hemophilia A: restores deficient factor VIII activity to achieve effective clot formation.
  • Von Willebrand disease: provides von Willebrand factor to improve platelet adhesion and stabilize factor VIII.
  • Surgical or procedural bleeding in affected patients: supplies necessary clotting factors to attain hemostasis during invasive procedures.

How It Works

  • Immunate supplies exogenous human factor VIII and von Willebrand factor, which bind to exposed subendothelial collagen and platelets, facilitating platelet adhesion and aggregation. The added factor VIII participates in the intrinsic tenase complex, accelerating the conversion of factor X to Xa, while von Willebrand factor stabilizes circulating factor VIII and mediates platelet tethering, collectively restoring normal hemostasis.

Side Effects

Immunate may be associated with infusion-related and immunologic reactions.

Common Side Effects

  • Mild fever or chills during or after infusion
  • Headache or dizziness
  • Nausea or vomiting
  • Arthralgia or muscle aches
  • Transient hypotension
  • Local site erythema or swelling

Serious or Rare Side Effects

  • Anaphylactic or severe allergic reaction
  • Development of inhibitory antibodies against factor VIII or VWF
  • Thromboembolic events (deep vein thrombosis, pulmonary embolism)
  • Renal impairment or hemolysis
  • Severe bleeding due to inadequate factor activity
  • Disseminated intravascular coagulation (rare)

Precautions & Warnings

  • Prior to administration, clinicians should assess patient history and monitor for specific risks.
  • Monitor for inhibitor development: test for anti‑factor VIII antibodies regularly.
  • Assess for allergic reactions: observe during initial infusion for signs of hypersensitivity.
  • Evaluate bleeding risk: ensure appropriate dosing based on severity of hemophilia or VWD.
  • Use caution in cardiovascular disease: avoid excessive pro‑coagulant activity.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Immunate can interact with other agents that affect coagulation or immune response.

Major Interactions (Avoid)

  • Concurrent use of other factor VIII concentrates may increase inhibitor formation risk.
  • Co‑administration with anticoagulants (e.g., warfarin, direct oral anticoagulants) may diminish hemostatic efficacy.
  • Use with desmopressin in VWD patients may lead to excessive VWF levels.

Moderate Interactions (Monitor Closely)

  • Immunosuppressive therapy may alter antibody response to the product.
  • Concomitant use of high‑dose steroids could mask infusion reactions.
  • Certain antibiotics (e.g., beta‑lactams) may increase risk of hypersensitivity; monitor closely.

Frequently Asked Questions

Immunate is indicated for the replacement therapy of patients with hemophilia A and von Willebrand disease. It provides the missing clotting factors to help achieve normal hemostasis in individuals who have a deficiency of factor VIII, von Willebrand factor, or both.

The factor VIII component participates in the intrinsic coagulation cascade, accelerating the conversion of factor X to Xa, while the von Willebrand factor stabilizes factor VIII and promotes platelet adhesion to damaged vascular surfaces. Together they restore the normal clotting process.

The dose of Immunate is individualized and determined by the prescribing clinician based on the patient’s weight, severity of deficiency, and clinical situation. Dosing regimens are tailored to achieve target factor levels and are not standardized across all patients.

Safety data for Immunate in pregnancy and lactation are limited. The decision to use the product in pregnant or nursing women should be made by the treating physician after weighing potential benefits against any unknown risks to the mother and infant.

To place an order, submit an enquiry on the Immunate product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Immunate combines both factor VIII and von Willebrand factor in a single formulation, which can simplify treatment for patients who need both components. Alternative products may contain only one of the factors, requiring separate administrations. Clinical choice depends on the patient’s specific deficiency, inhibitor status, and physician preference.

Immunate must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Prior to use, inspect the vial for particulate matter or discoloration and allow it to reach room temperature if required by the administration protocol.

Immunate is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and volume are determined by the prescribing clinician, and patients are monitored for any adverse reactions during and after the administration.

Serious risks include the development of inhibitory antibodies against factor VIII or von Willebrand factor, severe allergic or anaphylactic reactions, and thromboembolic events. Prompt recognition and management of these events are essential, and patients should be monitored closely during treatment.

Immunate is contraindicated in patients with known hypersensitivity to any of its components, including human plasma‑derived proteins. Individuals with a history of severe allergic reactions to factor concentrates or those who have developed high‑titer inhibitors to factor VIII should not receive this product without specialist guidance.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Human Coagulation Factor Viii, Human Von Willebrand Factor

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT